Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A [EXTENSION OF 700195864]

Trial Profile

Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A [EXTENSION OF 700195864]

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2014

At a glance

  • Drugs Affitope AD03 (Primary) ; Alum
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors AFFiRiS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top